{"id":1129,"slug":"韩国干细胞丰胸-svf-脂肪来源基质血管组分-注射-属于合法的再生医疗项目吗","question":"韩国干细胞丰胸、SVF（脂肪来源基质血管组分）注射，属于合法的再生医疗项目吗？","intent":"commercial","language":"zh","url":"https://worldwiki.io/q/韩国干细胞丰胸-svf-脂肪来源基质血管组分-注射-属于合法的再生医疗项目吗","entity":{"slug":"regenerative-medicine","name":"Regenerative Medicine","url":"https://worldwiki.io/entity/regenerative-medicine"},"answer":{"short_answer":"所给资料没有把丰胸、塑形等医美项目列入任何一国已批准的再生医学适应证，也未收录任何机构对这类项目的效果或价格说明。美国 FDA 明确警告：干细胞、基质血管组分（SVF）、脐带血、羊水、华通胶和外泌体类产品，若未获许可而在临床试验之外销售，属于违法。[2][4] 韩国现行法律允许的「治疗」通道限定于危及生命、罕见或难治且无替代疗法的情形。[3] 若一家机构把 SVF 注射作为美容项目推销，应要求其出示该产品在韩国的批准或临床研究备案文件，并向 MFDS 核实。[1]","detailed_answer":"<p>三个可核查的事实：</p><ul><li>韩国 2025 年 2 月 21 日起的「治疗」通道，适用对象是<strong>危及生命、罕见或难治且无替代疗法</strong>的患者。[3]</li><li>美国 FDA 将未经许可、在临床试验之外销售的 SVF、干细胞、脐带血、羊水、华通胶和外泌体产品列为<strong>违法</strong>。[2][4]</li><li>关于自体脂肪来源 SVF 的临床安全性，有同行评议的文献综述可查（Stem Cell Research &amp; Therapy, 2026），可作为与医生讨论风险时的检索线索。[5]</li></ul><p>资料<strong>未涉及</strong>丰胸效果、脂肪存活率、并发症发生率等任何数字，遇到此类承诺应要求提供来源。</p>","format":"paragraph","confidence":75,"verified_at":null,"updated_at":"2026-09-21 09:03:04"},"sources":[{"id":3,"title":"Ministry of Food and Drug Safety — English site","url":"https://www.mfds.go.kr/eng/","publisher":"MFDS, Republic of Korea","type":"government","accessed_at":"2026-09-18 18:00:01"},{"id":2,"title":"FDA Warns About Stem Cell Therapies","url":"https://www.fda.gov/consumers/consumer-updates/fda-warns-about-stem-cell-therapies","publisher":"U.S. Food and Drug Administration","type":"government","accessed_at":"2026-09-15 01:35:59"},{"id":94,"title":"첨단재생의료 및 첨단바이오의약품 안전 및 지원에 관한 법률의 개정 및 시행과 그 시사점","url":"https://www.shinkim.com/kor/media/newsletter/2728","publisher":"법무법인(유) 세종","type":"industry","accessed_at":"2026-09-19 18:01:25"},{"id":96,"title":"Important Patient and Consumer Information About Regenerative Medicine Therapies","url":"https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies","publisher":"U.S. Food and Drug Administration","type":"government","accessed_at":"2026-09-18 18:00:38"},{"id":20,"title":"Safety profile of autologous adipose-derived stromal vascular fraction in clinical use: an exhaustive literature review","url":"https://pubmed.ncbi.nlm.nih.gov/41618435/","publisher":"Stem Cell Research & Therapy (2026)","type":"academic","accessed_at":"2026-09-20 18:01:27"}],"published_at":"2026-09-20 08:11:10"}